普瑞眼科
(301239)
| 流通市值：54.33亿 | | | 总市值：54.33亿 |
| 流通股本：1.50亿 | | | 总股本：1.50亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,459,262,003.44 | 742,251,316.24 | 2,678,279,126.15 | 2,136,699,863.8 |
| 营业收入 | 1,459,262,003.44 | 742,251,316.24 | 2,678,279,126.15 | 2,136,699,863.8 |
| 二、营业总成本 | 1,389,064,906.77 | 690,187,707.1 | 2,673,850,053.68 | 2,058,379,113.42 |
| 营业成本 | 917,406,717.06 | 450,241,377.42 | 1,687,832,030.1 | 1,292,699,357.3 |
| 税金及附加 | 3,111,003.37 | 668,121.07 | 8,819,236.18 | 5,579,082.07 |
| 销售费用 | 258,212,409.03 | 122,607,875.32 | 500,604,620.22 | 380,124,297.57 |
| 管理费用 | 161,219,013.72 | 92,308,072.7 | 383,488,577.44 | 313,459,703.55 |
| 研发费用 | 5,343,459.43 | 2,461,386.01 | 8,019,702.61 | 4,878,194.72 |
| 财务费用 | 43,772,304.16 | 21,900,874.58 | 85,085,887.13 | 61,638,478.21 |
| 其中:利息费用 | 42,615,673 | 20,911,445.04 | 87,087,453.29 | 65,415,378.64 |
| 其中:利息收入 | 2,464,186.62 | 1,415,598.8 | 8,541,563.38 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -90,787.56 | 103,300.11 | 93,335.51 | 957,667.21 |
| 加:投资收益 | -811,598.95 | 24,638.4 | -3,606,753.04 | 1,293,828.4 |
| 资产处置收益 | 346,152.23 | 86,946.38 | -926,552.68 | 7,529,705.83 |
| 资产减值损失(新) | -902,137.44 | -188,322.25 | -6,058,890.7 | -2,499,158.4 |
| 信用减值损失(新) | -1,298,793 | -63,346.75 | -461,642.53 | 252,090.63 |
| 其他收益 | 790,199.77 | 1,725,618.82 | 13,637,683.61 | 12,419,883.32 |
| 四、营业利润 | 68,230,131.72 | 53,752,443.85 | 7,106,252.64 | 98,274,767.37 |
| 加:营业外收入 | 694,466.14 | 409,080.73 | 1,919,098.85 | 1,038,426.23 |
| 减:营业外支出 | 8,214,568.12 | 2,298,143.43 | 35,048,397.49 | 25,631,575.73 |
| 五、利润总额 | 60,710,029.74 | 51,863,381.15 | -26,023,046 | 73,681,617.87 |
| 减:所得税费用 | 42,897,414.39 | 23,086,518.32 | 66,808,409.5 | 50,835,668.99 |
| 六、净利润 | 17,812,615.35 | 28,776,862.83 | -92,831,455.5 | 22,845,948.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 17,812,615.35 | 28,776,862.83 | -92,831,455.5 | 22,845,948.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 14,667,471.77 | 27,279,356.63 | -101,862,127.9 | 15,841,198.32 |
| 少数股东损益 | 3,145,143.58 | 1,497,506.2 | 9,030,672.4 | 7,004,750.56 |
| 扣除非经常损益后的净利润 | 20,780,937.27 | 28,315,487.26 | -85,222,036.06 | 18,313,278.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.18 | -0.68 | 0.11 |
| (二)稀释每股收益 | 0.1 | 0.18 | -0.68 | 0.11 |
| 八、其他综合收益 | - | - | 146,610.07 | - |
| 归属于母公司股东的其他综合收益 | - | - | 146,610.07 | - |
| 九、综合收益总额 | 17,812,615.35 | 28,776,862.83 | -92,684,845.43 | 22,845,948.88 |
| 归属于母公司股东的综合收益总额 | 14,667,471.77 | 27,279,356.63 | -101,715,517.83 | 15,841,198.32 |
| 归属于少数股东的综合收益总额 | 3,145,143.58 | 1,497,506.2 | 9,030,672.4 | 7,004,750.56 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |